Lupus erythematosus-like imiquimod reaction: A diagnostic pitfall

Journal of Cutaneous Pathology

Volumn 38, Issue 4, 2011, Pages 346-350

  Barr, Keira L ^a,b   Konia, Thomas H ^a   Fung, Maxwell A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT;

ACTINIC KERATOSIS; AGED; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; CHEMICALLY INDUCED DISORDER; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; MALE; SKIN DISEASE;

ADJUVANTS, IMMUNOLOGIC; AGED; AMINOQUINOLINES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNITY, CELLULAR; KERATOSIS, ACTINIC; MALE; SKIN DISEASES;

EID: 79951732489     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2010.01592.x     Document Type: Article

References (36)

1. Chang YC, Madkan V, Cook-Norris R, et al., Current and potential uses of imiquimod. South Med J 2005; 98: 913.
2. Gupta AK, Browne M, Bluhm R., Imiquimod: a review. J Cutan Med Surg 2002; 6: 554.
3. Woodmansee C, Pillow J, Skinner RB Jr., The role of topical immune response modifiers in skin cancer. Drugs 2006; 66: 1657.
4. Burns CA, Brown MD., Imiquimod for the treatment of skin cancer. Dermatol Clin 2005; 23: 151, vii.
5. Neville JA, Williford PM, Jorizzo JL., Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curretage. J Drugs Dermatol 2007; 6: 910.
6. Goldenberg G, Krowchuk DP, Jorizzo JL., Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 2006; 17: 121.
7. Gaspari AA., Mechanism of action and other potential roles of an immune response modifier. Cutis 2007; 79: 36.
8. Papadavid E, Stratigos AJ, Falagas ME., Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opin Pharmachother 2007; 8: 1743.
9. Taylor CL, Maslen M, Kapembwa M., A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect 2006; 82: 227.
10. Barr K, Fung M., Cutaneous histologic reaction after the use of imiquimod cream: a case report [Abstract]. J Cutan Pathol 2010; 37: 125.
11. Crowson AN, Magro CM, Mihm MC Jr., Interface dermatitis. Arch Pathol Lab Med 2008; 132: 652.
12. Sriprakash K, Godbolt A., Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma. Australas J Dermatol 2009; 50: 211.
13. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G., Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol 2009; 36: 878.
14. Bauza A, Del Pozo LJ, Saus C, Martin A., Pemphigus-like lesions induced by imiquimod. Clin Exp Dermatol 2009; 34: e60.
15. Schiller M, Metze D, Luger TA, Grabbe S, Munzer M., Immune response modifiers-mode of action. Exp Dermatol 2006; 15: 331.
16. Barnetson RS, Satchell A, Zhuang L, Slade HB, Halliday GM., Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 2004; 29: 639.
17. Ooi T, Barnetson RS, Zhuang L, et al., Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized control trial. Br J Dermatol 2006; 154: 72.
18. Wolf IH, Cerroni L, Kodama K, Kerl H., Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005; 141: 510.
19. Weedon D., The lichenoid reaction pattern (interface dermatitis). In Weedon's Skin Pathology. London: Churchill Livingstone, Elsevier, 2010; 36.
20. LeBoit PE., Interface dermatitis. How specific are its histopathologic features? Arch Dermatol 1993; 129: 1324.
21. Ackerman AB, Boer A, Bennin B, Gottlieb GJ., Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis, 3rd ed. New York: Ardor Scribendi, 2005.
22. Crowson AN, Magro CM., The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001; 28: 1.
23. De Giorgi V, Salvini C, Chiarugi A, et al., In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 2009; 48: 312.
24. Schön MP, Schön M., Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291.
25. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R., Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325.
26. Lafyatis R, Marshak-Rothstein A., Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9: 222.
27. Krieg AM, Vollmer J., Toll-like receptors 7, 8 and 9: linking innate immunity to autoimmunity. Immunol Rev 2007; 220: 251.
28. Wan-uk K, Sreih A, Richard B., Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun Rev 2009; 8: 204.
29. Baechler EC, Batliwalla FM, Karypis G, et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610.
30. Toro JR, Finlay D, Dou X, Zheng SC, LeBoit PE, Connolly MK., Detection of type cytokines in discoid lupus erythematosus. Arch Dermatol 2000; 136: 1497.
31. Stein LF, Saed GM, Fivenson DP., T-cell cytokine network in cutaneous lupus erythematosus. J Am Acad Dermatol 1997; 36: 191.
32. Marques ER, Lourenco SV, Lima DM, Nico MM., Oral lesions in lupus erythematosus-cytokines profiles of inflammatory infiltrate. J Cutan Pathol 2010; 37: 439.
33. Schön M, Bong AB, Drewniok C, et al., Tumor-selective induction of apoptosis and the small-molecular immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138.
34. Vidal D, Matias-Guiu X, Alomar A., Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004; 29: 518.
35. Vidal D, Matias-Guiu X, Alomar A., Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004; 151: 656.
36. Berman B, Sullivan T, De Araujo T, Nadji M., Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol 2003; 149: 59.